【論文・学会活動～英文原著～】熊本大学病院　乳腺・内分泌外科

論文・学会発表

英文原著

150: Pegram MD, Bondarenko I, Zorzetto MMC, Hingmire S, Iwase H, Krivorotko PV, Lee KS, Li RK, Pikiel J, Aggarwal R, Ewesuedo R, Freyman A, Li R, Vana A, Yin D, Zacharchuk C, Tan-Chiu E.
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Br J Cancer. 120(2):172-182, 2019.
149: Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M.
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
Breast Cancer. 2019 Feb 7. [Epub ahead of print]

148: Dogan S, Yamamoto-Ibusuki M, Andre F.
Funding sources of practice changing trials.
Ann Oncol 29(4):1063-1065, 2018.
147: Ohashi Y, Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Yoshida M, Fujimoto T.
Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.
Support Care Cancer. 26(3):933-945, 2018.
146: Inoue H, Shinojima N, Ueda R, Yamamoto K, Ishii N, Igata M, Kawashima J, Araki E, Iwase H, Mikami Y, Yano S, Mukasa A.
A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism.
World Neurosurg. 119:394-399, 2018.
145: Fujiki Y, Yamamoto Y, Sueta A, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Tomiguchi M, Takeshita T, Iwase H.
APOBEC3B gene expression is a novel predictive factor for pathological complete response to neoadjuvant chemotherapy, but not a prognostic factor in breast cancer patients treated with neoadjuvant chemotherapy.
Oncotarget 17;9(55): 30513-30526, 2018
144: Goto-yamaguchi L, Yamamoto-ibusuki M, Yamamoto Y, Fujiki Y, Tomiguchi M, Sueta A, Takeshita T, Iwase H.
Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
Breast Cancer Res Treat. 172, 2, 353-362, 2018.
143: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Iwase H.
ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Cancer Biomark. 22(2):345-350, 2018.
142: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Iwase H.
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Mol Cancer. 26;17(1):67, 2018.
141: Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S.　
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Jpn J Clin Oncol. 48(9):855-859, 2018.
140: Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M:
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.
ESMO Open F2018, 3 (2) e000314, 2018.
139: Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Curr Med Res Opin. 34(1):49-54, 2018.
138: Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Breast Cancer Res Treat. 2018 Sep 21. [Epub ahead of print]
137: Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M.
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.　
Int J Clin Oncol. 2018 Dec 4. [Epub ahead of print]

136: Iwata H, Masuda N, Yamamoto D, Sagara Y, Sato N, Yamamoto Y, Saito M, Fujita T, Oura S, Watanabe J, Tsukabe M, Horiguchi K, Hattori S, Matsuura Y, Kuroi K.
Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Breast Cancer Research and Treatment. 162, 3, 501-510, 2017
135: Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M.
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Breast Cancer Research and Treatment. 163, 3, 545-554, 2017
134: Dogan S, Yamamoto-Ibusuki M, Andre F.
Funding sources of practice changing trials.
Ann Oncol 2017 Dec 15. Doi
133: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H.
Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.
Translational Oncology. 10, 5, 766, 2017
132: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H.
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.
Oncotarget. 8, 32, 52142, 2017
131: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, Tomiguchi M, Murakami K, Omoto Y, Iwase H.
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
BMC Cancer. 17, 1, 786, 2017
130: Sueta A, Yamamoto Y, Tomiguchi M et al.
Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no-recurrence.
Oncotarget, 22;8(41): 69934-69944, 2017
129: Guo J, Sueta A, Nakamura K, Yoshimoto N, Baba M, Ishida N, Hagio K, Toyama T, Iwase H, Tamakoshi A, Yamashita H.
Genetic and environmental factors and serum hormones and risk of estrogen receptor-positive breast cancer in pre-and postmenopausal Japanese women.
Oncotarget 11;8(39): 65759-65769, 2017

128: Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M.
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.
BMC Cancer. 16, 230, 2016
127: Aihara T, Toyama T, Takahashi M, Yamamoto Y, Hara F, Akabane H, Fujisawa T, Ishikawa T, Nagai S, Nakamura R, Tsurutani J, Ito Y, Mukai H.
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.
Breast Cancer. 23, 3, 329-342, 2016
126: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
Oncotarget. 7, 22, 32504, 2016
125: Tomiguchi M, Yamamoto Y,* Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Fujiwara S, Sueta A, Hayashi M, Takeshita T, Inao T. & Iwase H.
Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive / human epidermal growth factor receptor-2-negative primary breast cancer.
Cancer Sci. 107, 491-498, 2016
124: Tomiguchi M, Yamamoto Y,* Hayashi M, Yamamoto-Ibusuki M, Murakami K & Iwase H.
Docetaxel and cycrophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report.
Int Canc Conf J. 5, 202-205, 2016
123: Yoshitaka Fujiki, Lisa Goto, Yutaka Yamamoto, Takashi Takeshita, Mutsuko Yamamoto-Ibusuki, Hirotaka Iwase.
A case of premenopausal breast cancer with symptomatic cerebellar metastasis successfully treated by systemic endocrine therapy alone: relationship to biological features.
International Cancer Conference Journal, 6, 2, 55, 2016
122: Tomiguchi M, Yamamoto-Ibusuki M, Yamamoto Y, Fujisue M, Shiraishi S, Inao T, Murakami KI, Honda Y, Yamashita Y, Iyama KI, Iwase H.
Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer.
Surg Today., 46, 2, 214-23, 2016
121: Tomiguchi M, Yamamoto Y Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Fujiwara S, Sueta A, Hayashi M, Takashi T, Inao T, Iwase H.
FGFR1 protein expression is associated with prognosis in ER-positive/HER2-negative primary breast cancer.
Cancer Sci., ahead of print, 2016

120: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.
Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.
Trans Res., 166, 6, 540-553 e2, 2015
119: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Cancer Sci., 106, 11, 1582-9, 2015
118: Omoto Y, Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Sueta A, Fujiwara S, Taguchi T, Iwase H.
Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.
Springer plus, 5, 4, 108, 2015
117: Maneix L, Antonson P, Humire P, Rochel-Maia S, Castañeda J, Omoto Y, Kim HJ, Warner M, Gustafsson JÅ.
Estrogen receptor β exon 3-deleted mouse: The importance of non-ERE pathways in ERβ signaling.
Proc Natl Acad Sci USA, 112, 16, 5135-40, 2015
116: Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, Shien T, Tanaka S, Arima N, Komoike Y, Taguchi T, Iwase T, Inaji H, Ishitobi M.
Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence.
Eur J Surg Oncol. 41, 4, 548, 2015
115: Osako T, Nishimura R, Nishiyama Y, Okumura Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y, Arima N.
Efficacy of intraoperative entire-circumferential frozen section analysis of lumpectomy margins during breast-conserving surgery for breast cancer.
Int J Clin Oncol., ahead of print. 2015
114: Nakano M, Fujisue M, Tashima R, Okumura Y, Nishiyama Y, Ohsako T, Toyozumi Y, Arima N, Nishimura R.
Survival time according to the year of recurrence and subtype in recurrent breast cancer.
Breast, 24, 5, 588-593, 2015
113: Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, Fujisue M, Toyozumi Y, Arima N.
Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer: A retrospective study.
PLoS One, 10, 7, 2015
112: Arima N, Nishimura R, Osako T, Nishiyama Y, Fujisue M, Okumura Y, Nakano M, Tashima R, Toyozumi Y.
The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index.
J Clin Patho., ahead of print, 2015
110: Arima N, Nishimura R, Osako T, Nishiyama Y, Fujisue M, Okumura Y, Nakano M, Tashima R, Toyozumi Y.
A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer.
Oncology. ahead of print, 2015
109: Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S; Japanese Breast Cancer Society.
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.
Breast Cancer, 22, 1, 5, 2015
108: Imamura T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, Kariu T, Iwase H.
Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
Breast Cancer. ahead of print, 2015
107: Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Omoto Y, Iwase H.
Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer.
Int J Oncol., 46, 5, 2143-53, 2015
106: Yamamoto-Ibusuki M, Yamamoto Y, Fujiwara S, Sueta A, Yamamoto S, Hayashi M, Tomiguchi M, Takeshita T, Iwase H.
C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients.
Eur J Hum Genet.,23, 7, 949-56, 2015
105: Tomita S, Abdalla MO, Fujiwara S, Matsumori H, Maehara K, Ohkawa Y, Iwase H, Saitoh N, Nakao M.
A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation.
Nat Commun., 29, 6, 6966, 2015
104: Masuda T, Endo M, Yamamoto Y, Odagiri H, Kadomatsu T, Nakamura T, Tanoue H, Ito H, Yugami M, Miyata K, Morinaga J, Horiguchi H, Motokawa I, Terada K, Morioka MS, Manabe I, Iwase H, Mizuta H, Oike Y.
ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling.
Sci Rep. 16, 5, 9170, 2015
103: Nakamura T, Shinriki S, Jono H, Guo J, Ueda M, Hayashi M, Yamashita S, Zijlstra A, Nakayama H, Hiraki A, Shinohara M, Ando Y.
Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells.
Oncotarget. 20, 6, 1008-19, 2015
102: Nakamura T, Shinriki S, Jono H, Ueda M, Nagata M, Guo J, Hayashi M, Yoshida R, Ota T, Ota K, Kawahara K, Nakagawa Y, Yamashita S, Nakayama H, Hiraki A, Shinohara M, Ando Y.
Osteopontin-integrin αvβ3 axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma.
FEBS Lett. 16, 589, 231-9, 2015
101: Hayashi M, Yamamoto Y, Sueta A, Tomiguchi M, Yamamoto-Ibusuki M, Kawasoe T, Hamada A, Iwase H.
Associations between elastography findings and clinicopathological factors in breast cancer.
Medicine (Baltimore). 94, 50, e2290, 2015

100: Saori Fujiwara1, Mutsuko Yamamoto-Ibusuk1, Yutaka Yamamoto, Satoko Yamamoto, Mai Tomiguchi, Takashi Takeshita, Mitsuhiro Hayashi, Aiko Sueta, and Hirotaka Iwase.
The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
Oncotarget, 5, 11, 3931-3943, 2014
099: Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M, Gustafsson JÅ.
Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer.
Proc Natl Acad Sci USA, 111, 5, 1933-8, 2014
098: Ishitobi M, Okumura Y, Nishimura R, Nakatsukasa K, Tanabe M, Yoshida A, Masuda N, Shien T, Tanaka S, Komoike Y, Arima N, Taguchi T, Inaji H.
Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR.
Breast Cancer, 21, 6, 754, 2014
097: Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y, Arima N.
Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer.
Mol Clin Oncol., 2, 6, 1062-68, 2014
096: Endo M, Yamamoto Y, Nakano M, Masuda T, Odagiri H, Horiguchi H, Miyata K, Kadomatsu T, Motokawa I, Okada S, Iwase H, Oike Y.
Serum ANGPTL2 levels reflect clinical features of breast cancer patients: implications for the pathogenesis of breast cancer metastasis.
Int Biol Makers 29, 3, e239-45, 2014
095: Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M.
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Int J Clin Oncol., 19, 4, 607-613, 2014
094: Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Iwase H.
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
PLoS One, 9, 12, 2014
093: Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, Murakami K, Iwase H.
Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
Surgery, 155, 5, 927-35, 2014
092: Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y.
Clinical significance of CYLD downregulation in breast cancer.
Breast Cancer Res Treat., 143, 447-57, 2014
091: Guo J, Shinriki S, Su Y, Nakamura T, Hayashi M, Tsuda Y, Murakami Y, Tasaki M, Hide T, Takezaki T, Kuratsu J, Yamashita S, Ueda M, Li JD, Ando Y, Jono H.
Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
Oncotarget. 5, 15, 6353-64, 2014
090: Shinriki S, Jono H, Ueda M, Obayashi K, Nakamura T, Ota K, Ota T, Sueyoshi T, Guo J, Hayashi M, Hiraki A, Nakayama H, Yamashita S, Shinohara M, Ando Y.
Stromal expression of neutrophil galatinase-associated lopocalin correlates with poor differentiation and adverse prognosis in oral squarnous cell carcinoma.
Histopathology. 64, 256-64, 2014

089: Ishitobi M, Okumura Y, Arima N, Yoshida A, Nakatsukasa K, Iwase T, Shien T, Masuda N, Tanaka S, Tanabe M, Tanaka T, Komoike Y, Taguchi T, Nishimura R, Inaji H.
Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
Ann Surg Oncol. 20 6 1886 2013
088: Fujisue M, Nishimura R, Okumura Y, Tashima R, Nishiyama Y, Osako T, Toyozumi Y, Arima N.
Clinical Significance of CK19 Negative Breast Cancer.
Cancers. 5 1 1-11 2013
087: Hayashi M, Yamamoto Y, Takata N, Iwase H.
A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character.
SpringerPlus. 2 1 272 2013
086: Ibusuki M, Fu P, Yamamoto S, Fujiwara S, Yamamoto Y, Honda Y, Iyama KI, Iwase H.
Establishment of a standardized gene-expression analysis system using formalin-fixed, paraffin-embedded, breast cancer specimens.
Breast Cancer. 20 2 159-66 2013
085: Ishitobi M, Okumura Y, Nishimura R, Nakatsukasa K, Tanabe M, Yoshida A, Masuda N, Shien T, Tanaka S, Komoike Y, Arima N, Taguchi T, Inaji H.
Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR.
Breast Cancer. 2013
084: Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami KI, Okumura Y, Tomita S, Inao T, Honda Y, Omoto Y, Iyama KI.
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
Br J Cancer. 109 6 1537-42 2013
083: Iwata H, Masuda N, Sagara Y, Kinoshita T, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Tsuda H, Hayashi N, Noguchi S.
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Cancer. 119 4 704-713 2013
082: Kikuchi S, Nishimura R, Osako T, Okumura Y, Nishiyama Y, Toyozumi Y, Arima N.
Definition of p53 Overexpression and its Association with the Clinicopathological Features in Luminal/HER2-negative Breast Cancer.
Anticancer Res. 33 9 3891 2013
081: Matic M, Bryzgalova G, Gao H, Antonson P, Humire P, Omoto Y, Portwood N, Pramfalk C, Efendic S, Berggren PO, Gustafsson JÅ, Dahlman-Wright K.
Estrogen signalling and the metabolic syndrome: targeting the hepatic estrogen receptor alpha action.
PLoS One. 8 2 e57458 2013
080: Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y.
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Breast Cancer. 13-feb Epub adhead of print 2013
079: Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M.
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.
Breast Cancer Res Treat. 12-okt Epub adhead of print 2013
078: Shinriki S, Jono H, Ueda M, Obayashi K, Nakamura T, Ota K, Ota T, Sueyoshi T, Guo J, Hayashi M, Hiraki A, Nakayama H, Yamashita S, Shinohara M, Ando Y.
Stromal Expression of Neutrophil Gelatinase-Associated Lipocalin Correlates with Poor Differentiation and Adverse Prognosis in Oral Squamous Cell Carcinoma.
Histopathology. in press 2013
077: Takeshita T, Omoto Y, Yamamoto-Ibusuki M, Yamamoto Y, Iwase H.
Clinical significance of androgen receptor and its phosphorylated form in breast cancer.
Endocr Relat Cancer. 20 5 L15 2013
076: Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M.
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Int J Clin Oncol. 08-okt Epub adhead of print 2013
075: Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, Murakami K, Iwase H.
Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
Breast Cancer. 20 3 262-270 2013
074: Yamamoto S, Yamamoto-Ibusuki M, Yamamoto Y, Fujiwara S, Iwase H.
A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer.
BMC Cancer. 30 13 217 2013
073: Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, Toyama T, Chishima T, Saji S, Yamamoto-Ibusuki M, Iwase H.
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
BMC Cancer. 13 1 239 2013
072: Yamamoto-Ibusuki M, Yamamoto Y, Fu P, Yamamoto S, Fujiwara S, Honda Y, Iyama KI, Iwase H.
Divisional role of quantitative HER2 testing in breast cancer.
Breast Cancer. Epub ahead of print 2013
071: Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, Honda Y, Iyama KI, Iwase H.
Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
Mod Pathol. 26 1 79-86 2013
070: Takeshita T, Yamamoto-Ibusuki M, Yamamoto Y, Omoto Y, Honda Y, Iyama K, Zhang Z, Iwase H.
PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.
PLoS One. 8 11 e80552 2013
069: Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami KI, Okumura Y, Tomita S, Inao T, Honda Y, Omoto Y, Iyama KI.
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
Br J Cancer. 109 6 1537-42. 2013
068: Rezano A, Kuwahara K, Yamamoto-Ibusuki M, Kitabatake M, Moolthiya P, Phimsen S, Suda T, Tone S, Yamamoto Y, Iwase H, Sakaguchi N.
Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.
BMC Cancer. 13 562 2013
067: Takeshita T, Yamamoto-Ibusuki M, Yamamoto Y, Omoto Y, Honda Y, Iyama K, Zhang Z, Iwase H.
PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.
PLoS One. 8 11 e80552 2013

066: Sueta A, Ito H, Islam T, Hosono S, Watanabe M, Hirose K, Fujita T, Yatabe Y, Iwata H, Tajima K, Tanaka H, Iwase H, Matsuo K.
Differential impact of body mass index and its change on the risk of breast cancer by molecular subtype: A case-control study in Japanese women.
SpringerPlus. 1 1 39 2012
065: Antonson P, Omoto Y, Humire P, Gustafsson JÅ.
Generation of ERα-floxed and knockout mice using the Cre/LoxP system.
Biochem Biophys Res Commun. 424 4 710 2012
064: Endo M, Nakano M, Kadomatsu T, Fukuhara S, Kuroda H, Mikami S, Hato T, Aoi J, Horiguchi H, Miyata K, Odagiri H, Masuda T, Harada M, Horio H, Hishima T, Nomori H, Ito T, Yamamoto Y, Minami T, Okada S, Takahashi T, Mochizuki N, Iwase H, Oike Y.
Tumor Cell-Derived Angiopoietin-like Protein ANGPTL2 Is a Critical Driver of Metastasis.
Cancer Res. 72 7 1784-1794 2012
063: Fu P, Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, Zheng S, Iwase H.
Quantitative determination of insulin-like growth factor 1 receptor mRNA in formalin-fixed paraffin-embedded tissues of invasive breast cancer.
Breast Cancer. 19 4 321-328 2012
062: Fujiwara S, Yamamoto-Ibusuki M,Yamamoto S, Yamamoto Y, Iwase H.
Association of ErbB1-4 expression in invasive breast cancer with clinicopatholoical characteristics and prognosis.
Breast Cancer. 26-okt Epub adhead of print 2012
061: Hayashi M, Yamamoto Y, Ibusuki M, Fujiwara S, Yamamoto S, Tomita S, Nakano M, Murakami K, Iyama K, Iwase H
Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer.
Ann Surg Oncol. 19 9 3042-3049 2012
060: Kikuchi S, Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N.
Mucocele-like tumor associated with ductal carcinoma in situ diagnosed as mucinous carcinoma by fine-needle aspiration cytology: report of a case.
Surgery Today. 42 3 280-284 2012
059: Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S.
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Lancet Oncol. 13 4 345-352 2012
058: Osako T, Nishimura R, Okumura Y, Toyozumi Y, Arima N.
Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer.
Exp Ther Med. 3 1 66 2012
057: Sagara Y, Kamada Y, Yamamoto Y, Tanaka M, Kubo M, Yamaguchi R, Nishimura R, Mitsuyama S.
Study on the state of implementation of HER2 testing and positive ratios in patients with breast cancer in the Kyushu-Okinawa region of Japan.
Breast Cancer. Breast. 19 4 315-320 2012
056: Sawaki M, Mukai H, Tokudome N, Nakayama T, Taira N, Mizuno T, Yamamoto Y, Horio A, Watanabe T, Uemura Y, Ohashi Y.
Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
Breast Cancer. 19 3 253-258 2012
055: Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Ueno T, Sasano H, Toi M.
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.
Breast. 21 1 40-45 2012
054: Xu C, Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, Okumura Y, Yamaguchi L, Fujiki Y, Iwase H.
High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Breast Cancer. 12-sep Epub adhead of print 2012

053: Sueta A, Ito H, Kawase T, Hirose K, Hosono S, Yatabe Y, Tajima K, Tanaka H, Iwata H, Iwase H, Matsuo K.
A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population.
Breast Cancer Res Treat. 132 2 711-721 2011
052: Sueta A, Yamamoto Y, Inoue K, Kuriwaki K, Iwase H.
Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case.
Surg Today. 41 8 1145-9 2011
051: Fu P, Ibusuki M, Yamamoto Y, Hayashi M, Murakami K, Zheng S, Iwase H.
Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression.
Breast Cancer Res Treat. 130 1 307-317 2011
050: Hayashi M, Kai K, Okumura Y, Osako T, Arima N, Iwase H, Nishimura R.
Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy.
Oncology letters. 2 2 303-308 2011
049: Hayashi M, Okumura Y, Osako T, Toyozumi Y, Arima N, Iwase H, Nishimura R.
Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer.
Int J Clin Oncol. 16 6 694-700 2011
048: Ibusuki M, Yamamoto Y, Shinriki S, Ando Y, Iwase H.
Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients.
Cancer Sci. 102 2 439-45 2011
047: Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N.
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
World J Surg Oncol. 17 9 131 2011
046: Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y.
Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)].
Jpn J Clin Oncol. 41 5 709-712 2011
045: Shinriki S, Jono H, Ueda M, Ota K, Ota T, Sueyoshi T, Oike Y, Ibusuki M, Hiraki A, Nakayama H, Shinohara M, Ando Y.
Interleukin-6 signaling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma.
J Pathol. 225 1 142-50 2011
044: Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H.
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Cancer Sci. 102 4 858-865 2011
043: Aoi J, Endo M, Kadomatsu T, Nakano M, Horiguchi H, Ogata A, Odagiri H, Yano M, Araki K, Jinnin M, Ito T, Hirakawa S, Ihn H, Oike Y.
Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis.
Cancer Res. 71 24 dec-04 2011
042: Asawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M, Ohta T.
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
Breast Cancer Res. 12 R17 2011

041: Ibusuki M, Yamamoto Y, Kawasoe T, Shiraishi S, Tomiguchi S, Yamashita Y, Honda Y, Iyama K, Iwase H.
Potential Advantage of Preoperative Three-Dimensional Mapping of Sentinel Nodes in Breast Cancer by a Hybrid Single Photon Emission CT (SPECT)/CT System.
Surg Oncol. 19 2 88-94 2010
040: Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Breast Cancer Res Treat. 122 2 395-407 2010
039: Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.
Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Breast Cancer. 27 2 118-124 2010
038: Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N.
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Breast Cancer. 17 4 269-275 2010
037: Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N.
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer.
Exp Ther Med. 1 5 747-754 2010
036: Shinriki S, Ueda M, Ota K, Nakamura M, Kudo M, Ibusuki M, Kim J, Yoshitake Y, Fukuma D, Jono H, Kuratsu JI, Shinohara M, Ando Y.
Aberrant expression of serum amyloid A in head and neck squamous cell carcinoma.
J Oral Pathol Med. 39 1 jul-41 2010
035: Tanaka M, Takamatsu Y, Anan K, Ohno S, Nishimura R, Yamamoto Y, Masuda N, Mitsuyama S, Tamura K;
Kyushu Breast Cancer Study Group Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Anticancer Drugs. 21 4 453-458 2010
034: Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, Kasahara Y, Ishikawa T, Sawaki M, Hozumi Y, Iwase H.
Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
Breast Cancer. 17 4 254-260 2010
033: Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikuta Y, Harao M, Imai K, Baba H, Iwase H, Nomori H, Takahashi K, Daigo Y, Tsunoda T, Nakamura Y, Sasaki Y, Nishimura Y.
The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy.
Int J Cancer. 126 9 2153-2163 2010

032: Ibusuki M, Fujimori H, Yamamoto Y, Ota K, Ueda M, Shinriki S, Taketomi M, Sakuma S, Shinohara, Iwase H.
Midkine in plasma as a novel breast cancer marker.
Cancer Sci. 100 9 1735-39 2009
031: Kai K, Arima N, Miyayama H, Yamamoto Y, Iwase H, Nishimura R.
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Breast Cancer. 16 1 42-48 2009
030: Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, Oike Y, Endo M, Ibusuki M, Hiraki A, Nakayama H, Yoshitake Y, Shinohara M, Ando Y.
Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Clin Cancer Res. 15 17 5426-34 2009
029: Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y, Iwase H.
Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
Cancer Sci. 100 6 1012-1007 2009
028: Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y.
No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.
Jpn J Clin Oncol. 39 10 651-656 2009
027: Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.
Clinical significance of basal-like subtype in triple-negative breast cancer.
Breast Cancer. 16 4 260-267 2009
026: Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H.
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Cancer Sci. 100 11 2028-2033 2009
025: Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Ibusuki M, Tomita S, Sugiura H, Kobayashi S, Fujii Y, Iwase H.
Nuclear Corepressor 1 Expression Predicts Response to First-line Endocrine Therapy for Breast Cancer Patients on Relapse.
Chin Med J (Engl). 122 15 1764-1768 2009

024: Ibusuki M, Hiraoka T, Kanemitsu K, Takamori H, Tsuji T.
A case of complete remission from pancreatic cancer by multi-resections of locally pancreatic recurrent sites and liver metastasis.
Surg Today. 38 6 563-6 2008
023: Kai K, Shimizu T, Sugihara E, Yamamoto Y, Iwase H, Saya H.
Mouse mammary gland reconstitution with extrinsic gene-transferred mammary epithelial cells in vitro and in vivo.
Inflammation and Regeneration 28 181-188 2008
022: Kai K, Zhang Z, Yamashita H, Yamamoto Y, Miura Y, Iwase H.
Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer.
BMC Cancer. 8 16-sep 262 2008
021: Nishimura R, Okumura Y, Arima N.
Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Breast Cancer. 15 1 57 2008
020: Okumura Y, Yamamoto Y, Zhang Z, Toyama T, Kawasoe T, Ibusuki M, Honda Y, Iyama K, Yamashita H, Iwase H.
Identification of Biomarkers in Ductal Carcinoma in situ of the Breast with microinvasion.
BMC Cancer. 8 06-okt 287 2008
019: Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, Fukuyoshi Y, Yamamoto Y, Sugiuchi H, Iwase H, Shinohara M, Ando Y.
Midkine as a prognostic biomarker in oral squamous cell carcinoma.
Br J Cancer. 99 655-662 2008
018: Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y.
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
BMC Cancer. 8 25-okt 309 2008
017: Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H.
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer.
Breast Cancer Res Treat. 110 465-475 2008
016: Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H.
Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.
Endocr Relat Cancer. 15 3 755-763 2008

015: Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y, Iwase H, Yamashita H.　
Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer.
Jpn J Clin Oncol. 37 8 575-582　2007
014: Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H.
Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer.
Jpn J Clin Oncol. 37 11 820-828 2007
013: Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y.
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.
Breast Cancer Res. 9 3 R34 2007
012: Yoshida N, Miyanari N, Yamamoto Y and Egami H.
Successful Treatment of Malignant Fibrous Histiocytoma Originating in the Chest Wall:Report of a Case.
Surg Today. 36 714-721 2007

011: Kai K, Nishimura R, Arima N, Miyayama H, Iwase H.
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Int J Clin Oncol. 11 6 426-433 2006
010: Kawasoe T, Yamamoto Y, Okumura Y, Iwase H.
A case report of paraneoplastic neurological syndrome associated with occult breast cancer.
Breast Cancer. 13 2 202 2006
009: Shim GJ, Gherman D, Kim HJ, Omoto Y, Iwase H, Bouton D, Kis LL, Andersson CT, Warner M, Gustafsson JA.
Differential expression of oestrogen receptors in human secondary lymphoid tissues.
J Pathol. 208 3 408-414 2006
008: Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H.
p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
Breast Cancer Res. 8 4 R48 2006
007: Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.　
Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
Breast Cancer. 13 1 74-83 2006
006: Yamashita T, Yamashita H, Itoh Y, Karamatsu S, Itoh K, Hara Y, Ando Y, Sugiura H, Kuzushima T, Toyama T, Iwata H, Kobayashi S, Iwase H.　
Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide for metastatic breast cancer.
Breast Cancer. 13 4 334-339　2006
005: Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H.
NCOR1 mRNA is an independent prognostic factor for breast cancer.
Cancer Lett. 237 1 123-129 2006
004: Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Iwase H.　
Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progression in breast cancer.
Clin Cancer Res. 12 6410-6414 2006

003: Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H.
Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.　
Breast Cancer Res. 7 5 R753-64 2005
002: Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H.
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast.
Breast Cancer Res Treat. 94 1 11-16 2005
001: Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H.
ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
Clin Cancer Res. 11 1 193-198 2005

論文・学会発表

英文原著

2019年

2018年

2017年

2016年

2015年

2014年

2013年

2012年

2011年

2010年

2009年

2008年

2007年

2006年

2005年